De Boer is a translational cardiologist; overall goal is to gain further insight in the processes of myocardial remodeling and prevent cardiovascular disease. He is experienced in conducting clinical and preclinical projects. His main research interests are myocardial remodeling, fibrosis, diabetes, cardio-oncology and genetics of heart failure. He is director of the experimental cardiology section of the UMC Groningen, the Netherlands. De Boer is active in ESC: he was an HFA Board member (2014-2020), member of the ESC Advocacy, Education and eHealth committees, and is currently liaison officer of the ESC Council on Cardio-Oncology.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease